-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

704.O2.6 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic Malignancies

Symposia: Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Lymphoid Leukemias, ALL, Hodgkin lymphoma, Adult, Acute Myeloid Malignancies, AML, MDS, Lymphomas, Clinical Practice (Health Services and Quality), Elderly, Translational Research, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chronic Myeloid Malignancies, Diseases, Treatment Considerations, Biological therapies, Immunotherapy, Lymphoid Malignancies, Young adult , Myeloid Malignancies, Miscellaneous Cellular Therapies, Study Population, Human, Measurable Residual Disease , Transplantation (Allogeneic and Autologous)
Monday, December 9, 2024: 2:45 PM-4:15 PM
Hall B (San Diego Convention Center)
Moderators:
Lekha Mikkilineni, MD, MA, and Natalie Grover, MD, NULL
Disclosures:
No relevant conflicts of interest to declare.
2:45 PM

Natalie Grover, MD1, Dominic Moore2*, Anastasia Ivanova, PhD2*, Anne W Beaven, MD2, Christopher Dittus, DO2, Catherine Joyce Arago Cheng, BS2*, Kelly Hoye2*, Caroline Babinec2*, Faith Brianne Buchanan, PA-C2*, Angela Denise Spruill, ANP2*, Ashley Zanter, ANP-BC, AOCNP2*, John West, PhD2*, J. Kaitlin Morrison, PhD2*, Paul Armistead, MD, PhD2*, Kimberly A. Kasow, DO2*, Jonathan Serody, MD2, Gianpietro Dotti, MD2* and Barbara Savoldo, MD, PhD2*

1University of North Carolina, Chapel Hill, NC
2Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

3:00 PM

Ana Carolina Caballero Gonzalez, MD1*, Laura Escribà-Garcia, PhD2*, Cristina Ujaldón-Miró, PhD2*, Paula Pujol Fernández2*, Rosanna Montserrat-Torres2*, Eva Escudero-López2*, Irene García-Cadenas, MD1*, Albert Esquirol, MD3*, Maria Guardiola-Perello2*, Paola Jara-Bustamante2*, Rodrigo Martino, MD3*, Jorge Sierra, MD3, Carmen Alvarez-Fernández, PhD2* and Javier Briones1*

1Hematology Service, Hospital Santa Creu i Sant Pau, Barcelona, Spain
2Institut Recerca Hospital de la Santa Creu i Sant Pau, Laboratory of Experimental Hematology-IIB, Barcelona, Spain
3Hematology and Hemotherapy Department, Hospital de la Sant Creu i Sant Pau. IIB-Sant Pau and José Carreras Leukemia Research Institutes. Universitat Autónoma de Barcelona, Barcelona, Spain

3:15 PM

Yongxian Hu1,2,3*, Yali Zhou, PhD4*, Mingming Zhang1,5,6*, Shan Fu2,5*, Yong Yu4*, Ming Gao4*, Ruimin Hong2,5,7*, Houli Zhao7*, Lu Han4*, Jiangtao Ren, PhD4* and He Huang, MD1,2,8,9*

1Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
2Institute of Hematology, Zhejiang University, Hangzhou, China
3Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
4Nanjing Bioheng Biotech Co., Ltd., Nanjing, China
5Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China
6The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangz, China
7Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
8Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
9Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University, Hangzhou, China

3:30 PM

Susan Bal, MD1*, Larry D Anderson Jr., MD, PhD2, Omar Nadeem, MD3, Jesús G. Berdeja, MD4, Adriana Rossi, MD, MSc5, Tara Gregory, MD6, Mehmet Hakan Koçoğlu, MD7*, Thomas G. Martin, MD8, Daniel N. Egan, MD9, Luciano J. Costa, MD, PhD10, Hongxiang Hu, PhD11*, Jinjie Chen, PhD11*, Chaoqun Mei, PhD11*, Naomey Sarkis, PharmD, RPh11*, Alok Shrestha, MSc11*, Safiyyah Ziyad, PhD11*, Wei-Ming Kao, MD, PhD11*, Allison J Kaeding, MD11*, Michael R. Burgess, MD, PhD11 and Myo Htut, MD12

1University of Alabama at Birmingham, Birmingham, AL
2Myeloma, Waldenstrom’s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
3Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA
4Sarah Cannon Cancer Center at Tennessee Oncology, Nashville, TN
5Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
6Sarah Cannon Cancer Network, Colorado Blood Cancer Institute, Denver, CO
7University of Maryland, Greenebaum Comprehensive Cancer, Baltimore, MD
8Department of Hematology, University of California at San Francisco, San Francisco, CA
9Swedish Cancer Institute, Seattle, WA
10Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Vestavia, AL
11Bristol Myers Squibb, Princeton, NJ
12Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA

3:45 PM

Hua Jiang, PhD1*, Lu Li1*, Kaili Chen, MD1*, Chunchen Yang, MD1*, Ruixue Ma1*, Liangyu Xie, MD1*, Can He, MD1*, Fang Feng1*, Hao Wu1*, Xiaomei Chen1*, Dan Li2*, Xianghai Cai2*, Jin Zhao3*, Tao Guan, PhD4*, Li Ma3*, Min Bai, PhD3*, Guoxiang Wu2*, Liping Su3 and Weijun Fu1*

1Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
2Novatim Immune Therapeutics (Zhejiang) Co., Ltd., Shanghai, China
3Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Taiyuan, China
4Department of Hematology, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, AL, China

4:00 PM

MHD Monzr M. Al Malki, MD1, Alla Keyzner, MD2, Uday Popat, MD3, Yi-Bin Chen, MD, MS4, Hyung C Suh, MD, PhD5, Tania Jain, MD6, Melhem M. Solh, MD7, Anson Snow, MD8, Saar Gill, MD, PhD9, Lohith Gowda, MD10*, Joseph Uberti, MD, PhD11, Erica Buonomo, PhD12*, Yun Wang, PhD12*, Nancy Nabilsi, PhD12*, Timothy White12*, Cuong Nguyen13*, Jim Murray12*, Gavin MacBeath, PhD12*, Chrystal Louis, MD, MPH12, Shrikanta Chattopadhyay, MD12, Michelle Matzko, MD, PhD14* and Ran Reshef, MD, MSc15

1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
2Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
3Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
4Hematopoietic Cell Transplant and Cell Therapy Program, Massachusetts General Hospital, Boston, MA
5Stem Cell Transplantation and Cellular Therapy Program, John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ
6Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
7Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA
8Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
9University of Pennsylvania, Philadelphia, PA
10Yale Cancer Center and Yale School of Medicine, New Haven, CT
11Karmanos Cancer Institute, Detroit, MI
12TScan Therapeutics, Waltham, MA
13Biostatistical Consulting, Lexington
14TScanTherapeutics, Waltham, MA
15Division of Hematology & Oncology, Columbia University Medical Center, New York

*signifies non-member of ASH